Mexican Pharma Roundup: February 2020
Below is a selection of top recent news from Mexican pharma and healthcare, including the healthcare reforms president Andres Manuel Lopez Obrador is prioritising, latest news on the INSABI program,…
UDIMEB was started back in the 1970s as Proyecto Factor de Transferencia (transfer factor project) by Dr Sergio Estrada-Parra, the father of immunology in Mexico and winner of the National Science Award in 2012, who deepened research on transfer factors to develop an immunomodulatory drug which could be used locally. Today UDIMEB is a three-armed institution which comprises UDIBI, a national laboratory unit offering R&D bioprocess services to the private industry and the academia; USEIC, an institution providing free clinical services in the field of immunology and alternative treatments based on transfer factors to more than 20,000 patients; and FARMA FT, the company in charge of manufacturing the immunomodulatory drug Transferon®.
Contact Details:
UDIMEB
Escuela Nacional de Ciencias Biológicas (ENCB) IPN.
Prolongación de Carpio y Plan de Ayala S/N
Col. Casco de Santo Tomas, Del. Miguel Hidalgo
C.P 11340 MÉXICO DF
MEXICO
Tel: +52 (55) 57296000
Website: http://udibi.com.mx/
Below is a selection of top recent news from Mexican pharma and healthcare, including the healthcare reforms president Andres Manuel Lopez Obrador is prioritising, latest news on the INSABI program,…
Between 2015 and 2017 PharmaBoardroom met with pharma country managers in Mexico who spoke about the challenges and opportunities present in the Mexican market. Since then, these five stakeholders have…
The United States Trade Representative Office has been engaging with a number of countries, including Mexico, to address concerns related to IP protection and enforcement and market access barriers for…
What traits, competencies and drivers do you need to be a successful pharma country manager in today’s dynamic Mexican pharma market? Jose Guerrero and Male Mejido from the Mexico office…
Cristobal Thompson of the AMIIF examines the steps forward that Mexican pharma has made in countering corruption, the areas in which urgent improvement is still needed, and outlines the three…
Cristobal Thompson is the executive director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). In this article, he introduces us to an exciting new youth program set up to improve…
Cristobal Thompson is the Executive Director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving health…
David Peña Castillo, president and founder of the Mexican Federation of Rare Diseases (FEMEXER), addresses the problem of patients deserting therapies. In Mexico, approximately 15 percent of patients treated…
Cristobal Thompson is the executive director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving health…
Cristobal Thompson is the Executive Director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving health…
Cristobal Thompson is the Executive Director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving…
David Peña Castillo is the President and founder of The Mexican Federation of Rare Diseases (FEMEXER). Here he discusses what makes a patients association. When we find a way to…
See our Cookie Privacy Policy Here
